Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial. There is currently no approved vaccine or therapeutic to prevent or treat COVID-19. For information about enrolling in the trial, please click here.
Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2). There is currently no approved vaccine or therapeutic to prevent or treat COVID-19, which has been spreading worldwide since cases were first reported in December 2019 in Wuhan, Hubei Province, China.
March 3, 2020
Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest-established HIV research network, will make 28 presentations at the Conference on Retroviruses and Opportunistic Infections (CROI 2020) held in Boston, March 8-11. ACTG investigators will present data in oral presentations and themed discussions on the impact of chronic antiretroviral therapy (ART) on a novel metric of the HIV reservoir, predictors of multidrug resistant tuberculosis (MDR-TB) in resource-limited settings, findings from the first HIV cure trial that exclusively enrolled women, and interactions between contraceptives and TB drugs and the vaginal microbiome.
July 15, 2019
Los Angeles, Calif. – Investigators from the AIDS Clinical Trials Group (ACTG), the world’s largest and longest-established HIV research network, today announced that the Journal of Clinical Investigation published new findings from the ACTG HIV Reservoirs Cohort Study (A5321). The study found that HIV DNA remained in the cerebrospinal fluid of half of participants with well-managed HIV (virologic suppression in the plasma), confirming that the central nervous system (CNS) is a major reservoir for latent HIV. Individuals who harbored HIV DNA in the cerebrospinal fluid were more likely than other study participants to experience cognitive deficits on neurocognitive testing.
February 26, 2019
The AIDS Clinical Trials Group (ACTG), the world’s largest and longest-established HIV research network, funded by NIAID at the U.S. NIH, will make 11 oral and 19 poster presentations at CROI 2019 (Seattle, March 4-7). Several have the potential to influence clinical practice and guidelines for care.
“For more than 30 years, the ACTG has been at the forefront of research to treat HIV and its coinfections and comorbidities,“ said ACTG Chair Judith Currier, M.D., MSc of the University of California Los Angeles. “These studies represent the breadth of ACTG investigations and offer important insights into the treatment of MDR-TB, how to approach antiretroviral treatment in resource-limited settings, and strategies to address chronic complications of HIV.”